Improved Immunogenicity of Pneumococcal Vaccine in HIV Patients with Toll-like Receptor Agonist Adjuvant
Improved Immunogenicity of Pneumococcal Vaccine in HIV Patients with Toll-like Receptor Agonist Adjuvant
Abstract & Commentary
By Dean L. Winslow, MD, FACP, FIDSA, Chief, Division of AIDS Medicine, Santa Clara Valley, Medical Center; Clinical Professor, Stanford University School of Medicine, is Associate Editor for Infectious Disease Alert.
Synopsis: CPG 7909 is a toll-like receptor 9 (TLR9) agonist and vaccine adjuvant. In a randomized, double-blind, placebo-controlled trial, CPG 7909 was studied in combination with 7-valent pneumococcal conjugate vaccine (PCV7) given at 0 and 3 months and 23-valent pneumococcal polysaccharide vaccine (PPV23) given at 9 months; 97 patients were studied. The addition of CPG 7909 significantly enhanced the proportion of vaccine-high responders.
Source: Segaard OS, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: A randomized, controlled trial. Clin Infect Dis. 2010;51:42-50.
CPG 7909 1 mg added to vaccine was studied in a randomized, double-blind, placebo-controlled trial in combination with PCV7 given at time 0 and 3 months and PPV23 given at nine months in a trial with 97 HIV-infected adult patients. (Control patients received phosphate-buffered saline.) The primary endpoint was the proportion of vaccine-high responders at nine months (as defined as a two-fold increase in IgG levels to >= 1 ug/mL for at least five of the seven PCV7 pneumococcal capsular serotypes). The proportion of vaccine-high responders at nine months in the treatment group was 48.8% vs. 25% in the control group. The proportion of high responders also was greater at all other time points (51.1% vs. 39.6% at three months, 77.3% vs. 56.3% at four months, 87.8% vs. 51.1% at 10 months). Mild systemic and injection-site reactions were more common in the adjuvant group than in the control group (100% vs. 81.3%). No adverse effects on CD4+ cell count or organ dysfunction occurred in either group.
Commentary
High rates of invasive pneumococcal disease occur in HIV-infected patients despite effective HAART, and are a major cause of morbidity and mortality in HIV-infected patients at all CD4+ strata. PPV23 has limited efficacy in HIV-negative older adults,1-3 and even less efficacy in HIV-infected adults and children. While PCV7 has been very effective in preventing invasive pneumococcal disease in HIV-negative pediatric patients, a single injection of PCV7 has not been shown to be superior to PPV23 in HIV-infected adults.4-6
This study presents some good news for HIV-infected patients. While the trial excluded patients with CD4+ < 200 cells/uL, this study of largely HAART-treated patients (with median CD4+ count 673 and 605 in the adjuvant and control groups respectively) is representative of the majority of HIV-infected patients in many of our practices today. This TLR9 adjuvant represents some nice translational research that appears close to being available to help patients.
References
- Johnstone J, et al. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis. 2010;51:15-22.
- Moberly S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008: CD000422.
- Huss A, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48-58.
- Rodriguez-Barradas MC, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003;37:438-447.
- Kroon FP, et al. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine. 2000;19:886-894.
- Feikin DR, et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diagn Lab Immunol. 2004;11:137-141.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.